NMN (nicotinamide mononucleotide), NR (nicotinamide riboside), resveratrol, spermidine, fisetin, quercetin — the longevity supplement category is shaped by serious scientific research and marketed to a sophisticated consumer base. It is also one of the most claim-sensitive categories because the consumer-facing translation of aging research almost universally produces language that FDA classifies as disease claims or implied drug claims.
What FDA Permits for Longevity and Cellular Health Claims
Under 21 CFR 101.93(f), supplements may describe support for normal cellular and metabolic function. These are generally permissible:
"Supports healthy cellular energy production"
"Promotes healthy mitochondrial function"
"Supports healthy NAD+ levels"
"Promotes healthy aging"
"Supports cellular health"
"Helps maintain healthy DNA integrity"
"Supports healthy sirtuin activity"
"Promotes healthy telomere support"
"Supports the body's natural cellular renewal processes"
The key framing: support for normal cellular processes, not reversal of aging or treatment of age-related conditions.
Where Longevity Claims Cross the Line
Prohibited disease and drug claims:
"Reverses aging" — aging is a natural process; reversal implies treatment of a biological condition
"Slows cellular aging" — implies treatment of a measurable disease mechanism
"Repairs DNA damage" — DNA damage is a disease/injury state; repair is treatment
"Extends lifespan" — outcome claim for a biological endpoint that is not a normal function
"Reverses age-related decline" — explicitly references and implies treatment of an age-related disease state
"For age-related memory loss" — memory decline associated with aging is a clinical condition (MCI, dementia)
"Prevents age-related diseases" — disease prevention is a drug claim regardless of the mechanism
"Works like rapamycin" — references a prescription drug used for mTOR inhibition; implies equivalent drug-level treatment
Under 21 CFR 101.93(g)(2)(iii), a claim referencing a condition associated with a natural state (aging) can still be a disease claim if the condition causes significant harm. Age-related cognitive decline, cardiovascular aging, and metabolic decline associated with aging all meet that threshold.
NMN and NAD+ Precursors: The Drug Exclusion Problem
NMN has a significant regulatory complication beyond claim language. In 2022, FDA issued guidance indicating that NMN may be excluded from the dietary supplement definition under 21 U.S.C. 321(ff)(3)(B)(ii) because it had been authorized for investigation as a new drug (IND) before it was marketed as a supplement.
This does not necessarily mean NMN products are illegal — FDA enforcement has been limited and the legal status remains contested. But it creates dual exposure for NMN brands: claim compliance issues and potential ingredient legality questions. Products making aggressive longevity claims about NMN draw attention to both simultaneously.
Resveratrol: Evidence vs. Marketing
Resveratrol has been studied for effects on sirtuins, AMPK activation, and longevity pathways. The clinical evidence in humans is substantially weaker than the preclinical evidence that drove the original scientific interest. Structure/function claims about resveratrol supporting healthy cellular function may be substantiated at appropriate doses; claims that it activates longevity genes or extends healthy years are not substantiated by the current human evidence base and risk both FDA disease claim violations and FTC substantiation issues under 15 U.S.C. 45.
Telomere Claims
Telomere health has become a sub-category of longevity marketing. Claims about supporting healthy telomere length are generally treated as structure/function claims about normal cellular maintenance. Claims about reversing telomere shortening or preventing telomere-related aging cross into disease/treatment territory — telomere attrition is associated with disease states and premature aging conditions.
Longevity is one of the fastest-growing and most claim-risky categories in supplements
The scientific discourse around aging is genuinely exciting, and consumers are reading that research. But the language scientists use to describe aging mechanisms does not translate cleanly into permissible supplement claims — it almost uniformly produces disease claim language. Truli scans longevity supplement claims against 21 CFR 101.93(g) and flags NMN-specific ingredient legality issues, separating permissible cellular health claims from prohibited anti-aging disease claims.
A note from Truli: Truli is not a law firm, and this article does not constitute or contain legal advice or create an attorney-client relationship. When determining your obligations and compliance with respect to relevant laws and regulations, you should consult a licensed attorney.
